According to the clinical findings.

Mr. Altomari continued, Previous research have demonstrated that AG200-15 is definitely well-tolerated with a favorable breakthrough bleeding profile, suprisingly low rates of discomfort, and adhesion in real-world conditions over the 7-day time period of software. Agile’s patch is an elegant alternative to meet the guarantee of contraceptive patch technology. Agile’s Phase 2 open-label, crossover research compared the EE pharmacokinetic profile of AG200-15 to an oral contraceptive in healthy female volunteers. Thirty-two subjects were included in the analyses. The maximum plasma focus level was approximately 60 percent lower for AG200-15, and continuous state concentration levels were 15 percent-20 percent lower for AG200-15 in comparison to a 35 microgram OC .Comprehensive information on a lot more than 1,700 companies worldwide that received 10 or even more U.S. Patents in 2007 will be released in IFI’s Patent Cleverness and Technology Report, available in May. IFI produces regular monthly electronic updates of the report that monitor current patenting activity throughout the year. For ordering information, get in touch with IFI at 800-331-4955 or check out About IFI Patent Intelligence For more than 50 years, IFI Patent Intelligence , a Wolters Kluwer Health business, has been the preeminent producer of enhanced U.S patent databases. From the most rigorous U.S. Assignee name standardization process in the industry, to continual course code updates, and extensive indexing for chemical substance patents – – IFI has generated a solid status in patent databases.

Copyright blindserver.com 2017